Selective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide.
Reference facts
- Also known as
- Tymlos, BA058
- Category
- Bone & Calcium
- Mechanism of action
- Selective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide.
- Targets
- PTH1R (RG-biased)
- Indications under research or approved
- Postmenopausal osteoporosis (high fracture risk)
- Regulatory status (reference entry)
- FDA-approved (2017)
- Half-life
- ~1.7 hours
- Sequence
- AVSEHQLLHDKGKSIQDLRRRELLEKLLAKKLAH
- Sequence notes
- 34-residue PTHrP analog with multiple substitutions for selective PTH1R RG conformation activation.
- Molecular weight (Da)
- 3961
- Originator / sponsor
- Radius Health
- First reported
- 2008
Primary References
Explore research articles about Abaloparatide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.